Docstoc

RegenPRP Kit platelet rich plasma

Document Sample
RegenPRP Kit platelet rich plasma Powered By Docstoc
					                                                                           RegenLab Mollens-VD C.H.




                                       RegenPRP-Kit
                                           Medical Device IIa                 CE1250
                                          Platelet-Rich Plasma of RegenLab




                                                                    • Autologous preparation which
                                                                      increases the rate of healing
                                                                      process

                                                                    • Clinically proved reduction of
                                                                      wound pain

                                                                    • Efficiency proved in fields of :
                                                                      - surgery
                                                                      - dermatology
                                                                      - treatment of burns
                                                                      - dentistry

                                                                    • Efficiency proved in the
                                                                      autologous transplantation of
                                                                      cells and tissues

                                                                    • Preparation « point of care »
                                                                      (pre- or perioperative) simple,
                                                                      rapid, economic

                                                                    • Significant cost reduction of
                                                                      the treatment




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                                   -2-


Table of Contents
   In brief : the RegenPRP-Kit (platelet-rich plasma) of RegenLab ...........................................................................3
   Physiology of healing ..................................................................................................................................................4
   Can we increase the rate of healing process? ..........................................................................................................7
   The System “RegenPRP-Kit’’: .....................................................................................................................................8
   Laboratory studies of RegenPRP .............................................................................................................................10
   Clinical studies : applications of RegenPRP ...........................................................................................................13




Illustrations on the cover page:

 top:                       thrombocytes in their inactive disc form in the circulating blood

 down:                      activated thrombocytes forming pseudopodia in the blood clot




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                                 -3-                                                        RegenPRP-Kit


In brief :
the RegenPRP-Kit (platelet-rich plasma) of RegenLab

    •     Increase of the wound repair rate by local application of an autologous solution
          of plasma enriched with thrombocytes, derived from the blood’s patient.
    •     Its efficiency is proved in the domain of surgery, for treatment of severe burns
          and for the transplantation of cells and tissues.
    •     The preparation « point of care » pre- or perioperative of the PRP is simple, rapid
          and advantageous.

Increase of the hemostatic barrier formation, the                          Increase the tissue regeneration phase, by releasing
initial phase of the wound healing process, by locally                     various growth factors from activated thrombocytes,
increasing the rate and the amount of blood clothing                       which have been deposited in high concentration onto
formation. RegenPRP acts like an autologous                                the wound. Increase of the migration and mitosis rates
biological glue. It stops the bleeding and closes the                      of the stem cells for the regeneration of the damaged
wound and then prevents the contamination of the                           tissues. At the same time, growth factors of the plasma
wound by pathogenic agents (fungus, bacteria etc.)                         preparation locally stimulate the angiogenesis process,
Increase the rate of the inflammatory phase by the                         i.e. formation of the new blood vessels.
impregnation of the wound with the autologous signal                       Increase of the final phase of wound healing process,
proteins retrieved in the plasma preparation and                           consisting in the tissue restructuring:re-epithelization,
leukocytes. Chemoattraction of the micro- and the                          development of the local blood and lymphatic vessels,
macrophages required for the destruction of the                            formation of the bone matrix and its mineralisation.
pathogenic agents that may infiltrate the wound, and
for the elimination of dead and damaged cells.

                         Field of applications of the RegenPRP (platelet-rich plasma),
                            increase of the rate of healing and tissue restructuring

                                                                               DERMATOLOGY
                                      DENTAL MEDICINE                                                                RESEARCH &
          SURGERY                                                             INTERNAL MEDICINE
                                                                                                                    DEVELOPMENT
                                                                               GERONTOLOGY

                                         dental extraction                           cutaneous
    cardio-vascular surgery             dental implantation                     reconstruction and                    cell separation
                                                                                  transplantation
                                                                             ulcer and chronic wound
        abdominal surgery                                                              therapy                    autologous culture cell
                                                                             (e.g. after radio therapy)
                                                                                re-implantation of                autologous stem cells
     maxillo-facial surgery
                                                                                autologous cells,                        culture
                                                                               extemporaneous or
                                                                                cultivated in-vitro
        orthopedic surgery                                                                                            cell differential


   plastic and reconstructive                                                                                       tissue regeneration
             surgery


   treatment of severe burns                                                                                       healing remodelling




  RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                                 -4-




Physiology of the healing process


                                                                                                                            Tissue
                                                                                                                         restructuring
                              Closing of the wound


           Healing                                                                                 Tissue
                                                                                                regeneration
           process in
           presence of
           whole blood                                                     Inflammation


                                                              Hemostasis

                                                                                                               physiological process (time)



           Fig. 1



An injury resulting from an accident or a surgical                                    immediately change their appearance by forming
intervention damages destroys several tissues (epithe-                                pseudopodia. In the cell membrane of the
lium, conjunctive, fat, muscular, nervous, bone or carti-                             pseudopodia, various receptors are activated such as
lage tissues) and also the blood and lymphatic vessels.                               glycoproteins GPIIb and GPIIa. Some receptors bind to
Following such a trauma, the body reacts by a series of                               fibrinogen solubilized in the plasma, others bind to a
repairing steps called « healing cascade » (fig 1).                                   specific plasma proteins (von Willebrand Factor, vWF),
                                                                                      which have an affinity to naked subendothelial
Hemostatic phase                                                                      collagen. This initiates the platelet aggregation in the
The blood leaking from the damage blood vessels                                       wound: formation of local small platelet aggregats and
crosses the wound and forms a clot in few minutes. As                                 their adhesion to the naked subendothelial collagen
the result of clot formation, the bleeding is stopped and                             (fig. 2).
the wound is isolated from the outside environment.
The thrombocytes and the blood plasma play an                                         The activated thrombocytes release the thrombin,
essential role in the clot                                                            which will transform fibrinogen found in the plasma in
formation.                                                                                                           two peptide chains and
                                                                                                                     a fibrin . Monomers of
The thrombocytes pre-                                                                                                fibrin newly formed, will
sent     in   the    blood                                                                                           bind together to form a
circulation looks like a                                                                                             tridimensional network
disk having a smooth                                                                                                 of fibrin fibers into which
surface.     When       the                                                                                          the      platelets,     the
endothelial cells are                                                                                                leukocytes       and    the
destroyed, the collagen                                                                                              erythrocytes will be
threads made of fine                                                                                                 encaged. This process
fibers, located just under                                                                                           of      clot      formation
the endothelium, came                                                                                                prevents the blood to
in direct contact with the                                                                                           leak out from the injured
circulating blood. The                                                                                               blood vessels and also,
thrombocytes which re-                                                                                               to avoid the xenobiotic
mains attached to the                                                                                                or pathogenic agents to
lining of the injured                                                                                                enter in the blood
blood             vessels,                                                                                           circulation (fig. 3).



                                                     Fig. 2




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                                  -5-                                                      RegenPRP-Kit




                 Conversion      of    plasmatic     fibrinogen     into    fibrin
                 monomers


                 Formation of a tridimensional network by the binding
                 of the fibrin monomers


                 Encagement of erythrocytes, leukocytes and the
                 thrombocytes in the fibrin mesh allowing the clot
                 formation




          Fig. 3 : The biology of the wound : formation of the fibrin network




Inflammatory phase                                                          Afterwards these stem cells become functional
The leukocytes and the activated platelets, enclosed in                    cellswith specific functions. The leukocytes release
the clot, begin to release the signalisation proteins                      also a growth factor (VEGF), which induces the
(Chemiokines). This stimulates the leukocytes present                      creation of the blood vessels (angiogenesis).
in the blood vessels around the wound, and promotes                        Adhesion molecules, polypeptides, enzymes, vitamins
the migration of the macrophages from the conjunctive                      as well as oligo elements retrieved in the plasma, show
tissue. The function of the macrophages is to clean the                    a crucial role on the recruitment and the differentiation
wound from dead cells, damaged extracellular                               of the stem cells. These molecules are necessary to
structures and also, from the pathogenic agents which                      support the high level of metabolism associated with
could have invaded the wound. This clean up is                             these activated cells.
required for the following phase, the tissue
regeneration.                                                              However, erythrocytes entrapped in large numbers in
                                                                           the blood clot, do not seem to have a important role to
Tissue regeneration                                                        play in this process. They are eliminated by
The alpha granules of the activated thrombocytes,                          phagocytosis. All the important growth factors involved
embedded in the clot, release more and more growth                         in the healing process are shown in table 1.
factors. They induce the migration and the proliferation
of the non-differentiated mesenchymal cells.




  RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                       -6-




               Formation of tridimensional fibrin
                                        network



               Release of chemo-attractors and
                          growth factors by the
                  thrombocytes and leukocytes
                       present in the blood clot


                   Migration of leukocytes, tissue
                  macrophages and the stem cells
                       originated from the wound


                           Stem cells proliferation




                         Stem cells differentiation




          Fig. 4 : The biology of the wound : the proliferative matrix




         factor            name                             principal source         effects
           PDGF aa          platelet-derived growth         Activated thrombocytes   Mitogenes of the mesenchymal stem cells,
           PDGF bb          factors                                                  promote the synthesis of the extracellular matrix
           PDGF ab
           TGF-alpha        transforming growth factors     Activated thrombocytes   Stimulation of DNA synthesis, proliferation and
           TGF-beta                                                                  differentiation of various types of cells. Favorise
                                                                                     the synthesis of collagen.
           IGF-I            insulin-like growth factors    Activated thrombocytes Stimulates the proliferation and differentiation of
           IGF-II                                                                    osteoblasts.
           EGF              epidermal growth factor        Activated thrombocytes Stimulates the proliferation and differentiation of
                                                                                     the epidermic cells, co-stimulating angiogenesis.
           VEGF             vascular endothelial growth    leukocytes                Stimulate angiogenesis, chemo-attractor of
                            factor                         endothelial cells         osteoblasts
         In addition, the activated thrombocytes have onto their surface a multitude of signalisation molecules like e.g. CD9, CD-W17,
         CD31, CD41, CD42a-d, CD51, CD-W60, CD61, CD62P, CD63
         Table 1 : The growth factors acting on the healing cascade




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                                          -7-                                                         RegenPRP-Kit



Can we increase the rate of healing process?
The healing cascade shows that there are specific                                  The organic molecules isolated from a plasma pool or
components of blood plasma such as thrombocytes                                    manufactured by genetic engineering are by definition
and leukocytes, which are playing an important role in                             heterologous and are not specific to an individu. Their
all phase of tissue’s regeneration. Consequently, any                              precise dosage on an isolated wound is almost
attempt to increase the rate of the healing process                                impossible. Also, several growth factors synergically
must take in consideration these blood elements.                                   interact together. At any given time, the synergic effect
                                                                                   depends not only of the concentration of these growth
The signalisation molecules (e.g. the chemo-                                       molecules but also, of the concentration range of other
attractors), the growth factors (e.g. PDGF, platelet-                              molecules and ions (e.g. essential elements).
derived growth factor) and the other substances acting
on the wound (e.g. vitamins, essential elements) can                               Contrary to the abovementionned products, an
be purified by biotechnological processes from a                                   autologous plasma, extracted pre- or perioperative
plasma pool, manufactured by genetic engineering or                                from the patient himself, enriched in thrombocytes and
by chemical synthesis. They can be applied onto the                                also containing leukocytes, replies to the requirements
wound separately or in form of a mixture. However,                                 necessary for a product that intended to increase the
these products cannot be considered as physiological                               rate of healing process.
by definition.


    •    Leukocytes and thrombocytes, imbedded in the fibrin mesh, synthesize and release all
         molecules necessary for the healing process following a specific time sequence.
    •    The higher concentration of thrombocytes retrieved in the PRP, results in an increase of
         the amount of growth factors released. The healing process is then faster.
    •    The blood plasma of the patient contains all the supplementary factors (vitamins,
         essential elements etc.) for an optimal healing process.
    •    Because all constituents retrieved in the PRP are from autologous origin, the risk of a
         local immunological reaction is ruled out.
    •    The preparation of the RegenPRP required for a treatment, is simple, rapid and
         advantageous.


                                                                                                                         Tissue
                                 Closing of the wound




                                                                                                                      restructuring
               Healing with                                                                       Tissue
               a native clot,                                                                  regeneration
                      rich in
                                                                         Inflammation
               erythrocytes
                                                            Hemostasis

                                                                                                           physiological process (time)
                                     Closing of the wound




                Healing with
                     plasma
                     without
               erythrocytes
                  and rich in                                                    Due to the concentration of the specific proteins and
              thrombocytes                                                       the growth factors, the time of healing can be reduced
                (RegenPRP)                                                       in a significant manner

                                                                                                           physiological process (time)




              Fig. 5 : Reduction of the time frame of the « healing cascade » observed when the RegenPRP is used




  RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                      -8-




The System “RegenPRP-Kit’’:
During all steps of the development of the RegenPRP-Kit, the following objectives were pursuited:

    •    Kit for an easy preparation and « point of care » of an autologous plasma solution
         enriched in thrombocytes and leukocytes, having a minimal amount of erythrocytes, in
         order to obtain a « white clot » in the wound bed.
    •    Significant enrichment in locally acting growth factors and signal molecules to increase
         the rate of the healing process.
    •    Staunching (mechanical barrier) of the wound bed to prevent the infiltration of harmful
         agents (e.g. pathogenic agents).
    •    Production of a quantity of PRP to covert the size of the wound.


                                                       REGEN THT (CE1250)




                                                               A Vacutainer RegenTHT® empty

                                                               B Vacutainer RegenTHT® after blood withdrawal

                                                               C Vacutainer RegenTHT® after centrifugation at
                                                                 1 500 g for 8 minutes.




                 A                B                C

          Fig. 6 : Separation of the constituents of the
          blood with the Vacutainer RegenTHT®




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                               -9-                                                       RegenPRP-Kit



                                                                           Native blood                      Clot with
                                            Constituents
                                                                         Spontaneous clot                   RegenPRP


                                              erythrocytes              hematocrit of 35 – 50%          hematocrit of < 1%


                                                                                                         2 to 6 times more
                                             thrombocytes                 140 – 440 x 109/L
                                                                                                           concentrated

                                                                                                         2 to 6 times more
                                             growth factors              native concentration
                                                                                                           concentrated


                                                  fibrin                 native concentration           native concentration


                                                                                                         2 to 6 times more
                                               leukocytes                native concentration
                                                                                                           concentrated

      Tableau 2 : native clot (red) in comparison to the « white » clot produced with the RegenPRP




                   PRP from the RegenPRP-Kit                                   PRP from kit of another source

                  < 1% hematocrit (« white clot »)                              > 15% hematocrit (« red clot »)




              Fig. 7 : Comparison of RegenPRP with a PRP from another source on a healthy skin
                      left:     Application of 2ml of RegenPRP on healthy skin of the arm
                      right:    Application of 2ml of a PRP from another source



                   Vacutainer RegenTHT® (Thrombocyte Harvesting Tube)
           compared to other conventional tubes intended for in vitro diagnosis (IVD)
  Vacutainer RegenTHT®:                                             Conventional tubes for IVD

  •    developed for therapeutic application                        •     the IVD tubes are prohibited for therapeutic application
  •    anticoagulant ACD-A for an optimal preservation of           •     the anticoagulant EDTA damages the structure and function
       the structural and functional integrities of                       of cells, specially thrombocytes
       leukocytes and thrombocytes
  •    the separator gel in the Vacutainer RegenTHT®                •     the separator gel acts differently than the Vacutainer
       allows an excellent cell separation (optimal yield of              RegenTHT®
       the thrombocytes)
  •     ISO 10993 tested for its good tolerance and                 •     can contain traces of clotting activator and allergenic
       absence of allergic and mutagenic effects                          substances




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                                     - 10 -



Laboratory studies of RegenPRP



                                       Separation and enrichment of thrombocytes with the RegenPRP-Kit


                             700

                             600                                                             A     Whole blood
                             500
 Thrombocytes x 10 /L




                                                                                             B     Plasma before centrifugation
9




                             400

                             300
                                                                                             C     PRP (plasma rich in thrombocytes) after the 2nd
                                                                                                   centrifugation
                             200

                             100
                                                                                             D     PPP (Plasma poor in thrombocytes), super-
                                                                                                   natant after the 2nd centrifugation
                               0
                                       A           B           C            D


                        Fig. 8 The RegenPRP prepared according to the standard protocol (see page Error! Bookmark not defined.) shows a significant
                        increase in the concentration of thrombocytes




                                              Separation and enrichment in leukocytes, separation and
                                           reduction of the number of erythrocytes with the RegenPRP-Kit


                               16

                               14
                                                                                                          A    Whole blood

                               12                                                                         B    Plasma before centrifugation

                               10                                                                         C    PRP (plasma rich in thrombocytes)
                                                                                                               after the 2nd centrifugation
                                   8
                                                                                                          D    PPP (Plasma poor in thrombocytes),
    Erythrocytes x 10 /L




                                                                                                               supernatant after the 2nd centri-
                     12
    Leukocytes x 10 /L




                                   6
 9




                                                                                                               fugation
                                   4

                                   2

                                   0
                                           A             B              C              D


                           Fig. 9 : The RegenPRP prepared according to the standard protocol (see page Error! Bookmark not defined.) shows an important
                           increase in the number of leukocytes (in blue) and a significant reduction in the number of erythrocytes (in red).




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                                         - 11 -                                                                                         RegenPRP-Kit



     Stability of growth factors and specific plasma proteins retrieved into the RegenPRP
The preparation of the RegenPRP (platelet-rich plasma) with the RegenPRP-Kit is simple and rapid. Often, for
organisational or technical reasons, it is necessary to prepare the quantity of the PRP required for the patient’s therapy
the day before the operation. This is possible, because the growth factors and the plasma proteins, retrieved into the
RegenPRP, retain their biological activities for at least 20 hours, as long as PRP tubes are conserved at 4°C. Before
used, the PRP and the activator are simply warmed for 10 minutes at 37°C. The results of stability tests are shown in
figures 11 to 15.


                                                                                                                                                  PDGF aa


                                                                                                  3500




                                                                            concentration pg/ml
                                                                                                  3000
Concentration of PDGF aa (platelet derived                                                        2500
growth factor) at 0 hour and after 22 hours at                                                    2000
4°C. Preparation of the RegenPRP the day                                                          1500
before the operation. (Kit ELISA R&D)                                                             1000
                                                                                                   500
                                                                                                     0

                                                                                                                          O

                                                                                                                                22

                                                                                                                                      O

                                                                                                                                            22

                                                                                                                                                  O

                                                                                                                                                        22

                                                                                                                                                              O

                                                                                                                                                                   22
                                                                                                                        1T



                                                                                                                                     2T



                                                                                                                                                 3T



                                                                                                                                                             4T
                                                                                                                               1T



                                                                                                                                          2T



                                                                                                                                                       3T



                                                                                                                                                                  4T
                                                                                                                                          samples PRP 1 - 4


                                                                         Fig. 10


                                           TGF-beta 1


                            3500
      concentration pg/ml




                            3000
                            2500                                                                                          Concentration of TGF-beta 1 (transforming
                            2000                                                                                          growth factor) at 0 hour and after 22 hours at 4°C.
                            1500                                                                                          Preparation of the RegenPRP the day before the
                            1000                                                                                          operation. (Kit ELISA R&D)
                             500
                               0
                                   1TO 1T22 2TO 2T22 3TO 3T22 4TO 4T22
                                             samples PRP 1 - 4


  Fig. 11


                                                                                                                                                      EGF


                                                                                                                        3500

                                                                                                                        3000
  Concentration of EGF (epidermal growth
                                                                                                  concentration pg/ml




  factor) at 0 hour and after 22 hours at 4°C.                                                                          2500
  Preparation of the RegenPRP the day before                                                                            2000
  the operation. (Kit ELISA R&D)
                                                                                                                        1500

                                                                                                                        1000

                                                                                                                        500

                                                                                                                          0
                                                                                                                                1TO 1T22 2TO 2T22 3TO 3T22 4TO 4T22
                                                                                                                                                 samples PRP 1 - 4


                                                                          Fig. 12



  RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                                                                           - 12 -


                                                               VEGF


                            3500
      concentration pg/ml




                            3000                                                                                                     Concentration of VEGF (vascular endothelial
                            2500                                                                                                     growth factor) at 0 hour and after 22 hours at 4°C.
                            2000                                                                                                     Preparation of the RegenPRP the day before the
                            1500                                                                                                     operation. (Kit ELISA R&D)
                            1000
                            500
                              0
                                       1TO        1T22   2TO       2T22        3TO   3T22           4TO                 4T22
                                                              samples PRP 1 - 4


 Fig. 13



                                                                                                                                             FIBRONECTINE


                                                                                                                     1000
                                                                                               concentration pg/ml




                                                                                                                     800

 Concentration of the adhesion protein                                                                               600
 Fibronectin at 0 hour and after 22 hours
                                                                                                                     400
 at 4°C. Preparation of the RegenPRP the
 day before the operation. (Kit ELISA                                                                                200
 R&D)
                                                                                                                       0
                                                                                                                             1TO     1T22    2TO     2T22   3TO   3T22   4TO   4T22
                                                                                                                                                   samples PRP 1- 4


                                                                                          Fig. 14


                              2500
      concentration ng/ml




                              2000
                                                                                                                                 D-dimers in the whole blood
                              1500                                                                                               D-dimers in the PRP            The preparation of the
                                                                                                                                                                RegenPRP and the materials
                              1000
                                                                                                                                                                used do not change the
                               500                                                                                          subjects:                           concentration of D-dimers.
                                                                                                                            01 - 05 : healthy subjects
                                   0                                                                                        06 - 10 : diabetic subjects
                                       01    02     03   04   05   06     07    08   09   10

                                                               subjects


   Fig. 15 : Concentration of the coagulation markers, D-dimers, in whole blood and in the PRP
   samples of 10 adult subjects



                                            Labo-medical evaluation of PRP prepared with the RegenPRP-Kit

    •                       Effective separation and enrichment of the cells necessary for healing
                            (thrombocytes and leukocytes),
    •                       The stability of the growth factors for at least 20 hours is observed when PRP is
                            stored at 4°C,
    •                       The efficacity of coagulation factors is preserved.

     Prof. Dr. med. D. Hayoz, Divison of Hypertension and Vascular medicine, CHUV, Lausanne.


RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                                     - 13 -                                                  RegenPRP-Kit


Clinical studies : applications of RegenPRP

                                                              Plastic surgery
.

Deep burn of the inferior limb, required debridment and a thin skin graft.




             A                                                                      B

         A : site of graft sample
         B : site of the application of the graft
         Treatment of the two sites with RegenPRP to increase the healing rate. The graft was fixed uniquely with the
         PRP acting as a biologic glue.
         Result :      Rapid and complete healing of two sites.

Severe burn of 85% of the body surface




                             A                                       B

         Use of RegenPRP as autologous biological glue to fix the skin graft and autologous keratinocytes cultivated in
         vitro and also to increase the rate of healing,
         A : site of graft sample and the keratinocytes
         B : site of application
         Result :      Rapid healing of the sample site and the site of application.

PD, Dr. W. Raffoul. Plastic and Reconstructive surgery, Centre Hospitalier Universitaire Vaudois (CHUV), CH-1011 Lausanne



                                                          Orthopedic surgery
Fracture on a plasmacytoma which has been massively irradiated. Indication: surgical retaking of the delay of consolidation




         Result :   after 2 months, there iwas evidence of consolidation.

PD Dr. F. Chevalley, Orthopedic surgery, Centre Hospitalier Universitaire Vaudois (CHUV), CH-1011 Lausanne




    RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                         - 14 -




                                                                Plastic surgery
Randomised study of the transplantation of keratinocytes (in progress)

        Sites of graft sample treated with a suspension of keratinocytes in the RegenPRP :




                                                                                 B
                                                            A




       A:     Wound treated with RegenPRP. Healing was completed in 5 days.
              Photo at 20 days
       B:     Test : wound non treated.
              Photo at 30 days

        Result :    Macroscopic observation shows a particularly positive evolution on the site treated with RegenPRP.

PD Dr. W. Raffoul (1), Prof. Dr. D. Hayoz (2), Dr. M. Benathan (3)
(1) Plastic and reconstructive surgery, (2) Division of Hypertension and Vascular Medicine, (3) Dermatology laboratory, Centre Hospitalier
Universitaire Vaudois (CHUV), CH-1011 Lausanne




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
                                                                       - 15 -                                                        RegenPRP-Kit


                                                                  Dermatology

Voluminous ulcer secondary to a vascularitis, exposing the tendons .
      Status after vasculitis in an 83 year old patient, hospitalized for 3 months. Slow recovery after conventional treatment.




 A                                                    B                                                 C
        A : Presentation of the wound on the first day of the application of the RegenPRP (day 1)
        B : Presentation of the wound 20 days following a single application of the RegenPRP.
        C : Presentation of the wound 33 days following 2 applications of the RegenPRP

        Result :       Spectacular increase in the granular tissue covering tendons after 20 days. Rapid epidermization of the
                       upper part of the ulcer. Due to this evolution, the 83 years old patient who was hospitalized for 3 months,
                       can return home.


Post phlebitic ulcer
       Post phlebitic ulcer on the ankle cleaned in the budding phase in a 89 years old patient, hospitalised for 8 months. Difficult
       initiation of epidermization obtained after 4 years of dermatological treatment




A                                                     B                                                 C
        A : Presentation of the ulcer on the first day of the application of RegenPRP
        B : Presentation of the wound 20 days following a single application of RegenPRP
        C : Presentation of the wound 33 days following 2 applications of RegenPRP
        Result :    Epidermization on the periphery of the wound and fast progression of epidermization of the islets. The
                    patient can return home.

Dr. S. Cairey-Remonnay (Head of the clinic) and Dr. F. Aubin, Department of Dermatology, Centre Hospitalier Universitaire, Besançon (France)


Chronic Radiodermitisis
       Chronic Radiodermitisis after a superficial irradiation on an epidermoidal carcinoma of the skin, stationary for 18 months
       after conventional treatment.




                   A                                                                       B
        A : Presentation of the wound the day after the first application of RegenPRP.
        B : Evolution of the wound after 3 months of treatment and 5 applications of RegenPRP
        Result:     50% reduction of the wound surface

PD Dr. J. Bernier, Division of Radiotherapy and Nuclear Medicine, Ospedale San Giovanni, CH-6500 Bellinzona


  RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com
RegenPRP-Kit                                                     - 16 -




RegenLab SA – 5, rue de l’Eglise – C.H.-1146 Mollens-VD – Tel. +41 (0)21 864 38 00 – Fax +41 (0)21 864 38 01 – E-Mail : info@regenlab.com

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:361
posted:8/12/2011
language:English
pages:16